Abstract: Aspects and embodiments of the instant disclosure provide therapeutic methods and compositions comprising interleukin 12 (IL-12) useful for treating radiation-induced damage in a subject. In particular, the instant disclosure provides methods and compositions for radiation protection and/or radiation toxicity mitigation for the treatment of acute radiation syndrome and radiation induced toxicity associated with the treatment of cutaneous T-cell lymphoma.

Abstract: A transposable element is provided that as a 3? and a 5? end. The transposable element includes a 5? recombining site 5? of a nucleic acid sequence encoding a selectable marker, a 3? recombining site 3? of the nucleic acid sequence encoding a selectable marker, a nucleic acid sequence encoding and MHC epitope 5? to the 5? recombining site or 3? to the 3? recombining site, and an insertion end comprising an inverted repeat sequence sufficient for integration of the transposable element at the 5? and the 3? end of the transposable element. In one embodiment, a transposable element is provided that has a 5? and a 3? end. The transposable element includes a 5? loxP sequence 5? of a nucleic acid encoding a selectable marker, a 3? loxP sequences 3? of a nucleic acid encoding the selectable marker, an MHC epitope 5? to the 5? loxP sequences or 3? of the 3? loxP sequence, an insertion end at the 5? end of the transposable element, and an insertion end at the 3? of the transposable element.